*The search scope is limited to the products and news section of this site
*The search scope is limited to the products and news section of this site
▶ MTB-1806
MTB-1806 is a small-molecule drug candidate indicated for AIS, which is characterized by a sudden loss of blood circulation to an area in the brain, the corresponding lack of blood and oxygen supply resulting in nerve damage and loss of neurological function.
MTB-1806 has demonstrated good efficacy and safety in preclinical studies. Animal experiments have shown that MTB-1806 can significantly increase the inhibition rate of post ischemic cerebral infarction and reduce the infarct area after cerebral ischemia compared with NBP (an AIS drug approved by the NMPA) while performing well in terms of toxicity and tolerability. In addition, MTB-1806 demonstrated a favorable dose-effect relationship, and in a rat model, the PK of MTB-1806 was superior to that of NBP in terms of in vivo exposure and oral bioavailability. In vitro studies have shown that MTB-1806 had a half-life of 19.09 hours, which could support an once-a-day dosing.
Copyright © 2022 河南真实生物科技有限公司 All Rights Reserved 京ICP备2021026784号-1
